INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
Recruiting · NCT06949774 · Interventional (participants receive a specific treatment) · Lead sponsor: RAND
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.
Who can take part
Inclusion criteria
- Male and female clients age 18 and older.
- Started ART at Mildmay or another clinic within the preceding 2 months
- Able to speak and understand either English or Luganda.
- Have their own cell phone or have consistent access to someone else's phone.
- Willing to receive daily text messages for the 6 months of intervention duration.
- Willing and able to use the WisePill device distributed for adherence verification for the duration of the study.
Exclusion criteria
- Not mentally fit to consent.
- Language other than Luganda or English.
- Not willing to consistently use the Wisepill device for adherence measurement.
Where it is running
1 location listed.
- Mildmay Uganda - Kampala, Uganda